

Supporting Information

**Second Generation Specific-Enzyme-Activated
Rotaxane Propeptides**

**Antony Fernandes,^{a,b} Aurélien Viterisi,^a Vincent Aucagne,^{*c} David A. Leigh^{*a}
and Sébastien Papot^{*b}**

^a School of Chemistry, University of Edinburgh, The King's Buildings, West Mains Road, Edinburgh, EH9 3JJ.
Fax: (+44) 131-650-6453, <http://www.catenane.net> ; E-mail: david.leigh@ed.ac.uk

^b Université de Poitiers, UMR 6514 Laboratoire de Synthèse et Réactivité des Substances Naturelles, 40 Avenue
du Recteur Pineau, 86022 Poitiers (France) ; E-mail: sebastien.papot@univ-poitiers.fr

^c Centre de Biophysique Moléculaire, UPR 4301 CNRS, Rue Charles Sadron, 45071 Orléans, Cedex 2 (France) ;
E-mail: aucagne@cnrs-orleans.fr

Table of Contents

1. General Experimental Section	S2
Enzymatic Hydrolysis	S3
Solubility of Propeptides	S3
2. Synthetic Routes	S4
Scheme S1 - Synthesis of bis-Azido Rotaxane 1	S4
Scheme S2 - Synthesis of Functionalized Rotaxane Propeptides 2 and 3	S5
Scheme S3 - Synthesis of Propeptide 21 and Unfunctionalised Rotaxane 22	S5
Scheme S4 - Synthesis of Peptide 6	S6
Scheme S5 - Synthesis of Macrocycles 9 and 10	S7
3. Experimental Procedures	S8
4. Representative ¹H NMR Stack Plots	S29
5. Selected ¹H and ¹³C NMR Spectra	S30
6. References	S50

1. General Experimental Section

Unless otherwise stated, all reactions were run under an atmosphere of N₂. Prior to use, isophthaloyl dichloride was purified by recrystallization from hexane; *p*-xylylenediamine was purified by distillation under reduced pressure. Dry acetonitrile, chloroform, dichloromethane, *N,N*-dimethylformamide, methanol, tetrahydrofuran and toluene were obtained by passing these solvents through activated alumina columns on a PureSolv™ solvent purification system (Innovative Technologies, Inc., MA). Unless otherwise stated, all other reagents were purchased from commercial sources and used without further purification. Flash column chromatography was carried out using Kiesegel C60 (Fisher Scientific) as the stationary phase. Analytical TLC was performed on aluminium-backed sheets pre-coated with silica 60 F254 adsorbent (0.25 mm thick, Merck, Germany) and visualized under UV light. Preparative TLC was carried out using precoated silica gel plates (2000 μm thick, Silica gel GF, Uniplate, Germany). Size exclusion chromatography was performed using Toyopearl HW-405 (Tosoh, Japan) with methanol/chloroform in a 1:1 v/v ratio as the eluent. ¹H and ¹³C NMR spectra were recorded on a Bruker AV 400 instrument. Chemical shifts (δ) are reported in parts per million from low to high field and referenced to residual solvent. Coupling constants (*J*) are reported in hertz (Hz). Standard abbreviations indicating multiplicity are used as follows: b = broad, s = singlet, d = doublet, m = multiplet, q = quartet, quint. = quintet, t = triplet. All melting points were determined using a Sanyo Gallenkamp apparatus and are uncorrected. Analytical RP-HPLC was carried out on a Gilson instrument composed of 306 pumps, 811C dynamic mixer (100 μL), 806 manometric module and an Applied Biosciences 759A UV detector with a Phenomenex C18 (2) Luna column (2 x 250 mm, 5 μm, 100 Å). Chromatograms were recorded at 220 nm unless stated otherwise. H₂O and CH₃CN were used as mobile phase, buffered with TFA (0.1% v/v, pH ≈ 2). Preparative RP-HPLC was carried out on a Gilson instrument composed of 306 pumps, 811C dynamic mixer (1.5 mL), 806 manometric module and a 118 UV detector with a Spherisorb ODS2 column (21.2 x 250 mm, 5 μm, 100 Å), using H₂O and CH₃CN as mobile phase, buffered with HCOOH (6.6 mmol/L, pH ≈ 3). LCMS was carried out on a Finnigan Mat system composed of an LCQ mass spectrometer, P4000 pumps, and a UV2000 UV detector with a Phenomenex C18 (2) Luna column (2 x 250 mm, 5 μm, 100 Å). Chromatograms were recorded at 220 nm unless stated

otherwise. Low-resolution ESI spectra were recorded either on a Micromass ZMD or on a Finnigan Mat LCQ spectrometer. MALDI and high resolution ESI spectrometry were carried out by the EPSRC national mass spectrometry service centre (Swansea, UK). FAB mass spectrometry was carried out by the mass spectrometry service at the University of Edinburgh. Aldehyde **11**¹ and alkyne **17**² and were synthesized according to literature procedures.

Enzymatic Hydrolysis


Enzymatic hydrolysis was carried out with commercial β -galactosidase from *Escherichia coli* E.C. 3.2.1.23 (1000 units/mg protein (biuret), aqueous glycerol suspension (1:1), 10 mM Tris buffer salts and 10 mM magnesium chloride, pH 7.3). Prodrugs were incubated with the enzyme in phosphate buffer (0.02 M, pH 7.0) at 37°C. Aliquots (20 μ L) were periodically withdrawn from the medium and diluted into a solution of TFA (0.1%) in H₂O (40 μ L). Rate of hydrolysis was monitored by analytical HPLC and LCMS.

Solubility of Propeptides


A known quantity of each compound was dissolved in a known volume of DMSO/X/H₂O (X= MeOH, EtOH or CH₃CN depending on the solubility of each compound) and the solution was analyzed by HPLC. The absolute area of the peak of interest was then compared with the area of the peak produced by a saturated solution of the same compound in pure water at 20°C. Care was taken to record the chromatograms in the linearity regime of the UV detector (Manufacturer specifications: linearity: 1% when value is within sensitivity range of 0.001 to 2.0 A.U.) and final solubility are given with a maximum error of 10%.

2. Synthetic Routes


Scheme S1 - Synthesis of bis-Azido Rotaxane 1




Scheme S2 - Synthesis of Functionalized Rotaxane Propeptides 2 and 3




Scheme S3 - Synthesis of Propeptide 21 and Unfunctionalised Rotaxane 22




Scheme S4 - Synthesis of Peptide 6



Scheme S5 - Synthesis of Macrocycles 9 and 10




3. Experimental Procedures



CAS Registry Number: 125872-98-2


To a solution of 4-hydroxy-3-nitrobenzaldehyde (5.00 g, 29.94 mmol) in CH₃CN (200 mL) were added allyl bromide (10.40 mL, 4.0 equiv.) and K₂CO₃ (12.40 g, 3.0 equiv.). After being stirred at 60°C for 72 hours, the mixture was diluted with EtOAc and washed with water and brine. The combined organic layers were dried (MgSO₄), filtered and concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 7/3 then 6/4) afforded **11** (5.70 g, 27.54 mmol, 92%) as a pale yellow powder. The compound showed identical spectroscopic data to that reported in the literature.² ¹H NMR (400 MHz, CDCl₃): δ 9.91 (s, 1H, CHO), 8.32 (d, 1H, *J* = 2.0 Hz, H₁), 8.04 (dd, 1H, *J* = 8.8 Hz, *J* = 2.0 Hz, H₂), 7.21 (d, 1H, *J* = 8.8 Hz, H₃), 6.07 to 5.98 (m, 1H, H₅), 5.50 (dd, 1H, *J* = 17.6 Hz, *J* = 1.2 Hz, H₆), 5.37 (dd, 1H, *J* = 7.8 Hz, *J* = 1.2 Hz, H₆), 4.78 (dt, 2H, *J* = 4.8 Hz, *J* = 1.6 Hz, H₄).




CAS Registry Number: 914769-85-0

3-Nitro-4-(2-propenyloxy)benzaldehyde **11** (5.60 g, 27.05 mmol) was added in a 10 mL round-bottom flask equipped with a condenser and then heated at 160-165°C over a period of 17 hours. After allowing the dark brown mixture to reach room temperature, it was poured into 1M HCl and extracted with dichloromethane. The combined organic layers were dried with MgSO₄, filtered and concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 8/2 to 6/4) afforded **12** (3.20 g, 15.46 mmol, 57%) as a yellow powder and the remaining starting material **11**. The latter was put in a second run in the same conditions described before to afford 680 mg of **12** (3.29 mmol, 12%) resulting in a total yield of 69%. ¹H NMR (400 MHz, CDCl₃): δ 11.41 (bs, 1H, OH), 9.91 (s, 1H,

CHO), 8.51 (d, 1H, $J = 2.0$ Hz, H₁), 8.01 (d, 1H, $J = 2.0$ Hz, H₂), 6.03 to 5.93 (m, 1H, H₄), 5.20 to 5.18 (m, 1H, H₅), 5.16 (dq, 1H, $J = 11.2$ Hz, $J = 1.6$ Hz, H₅), 3.53 (d, 2H, $J = 6.8$ Hz, H₃); ¹³C NMR (100 MHz, CDCl₃): δ 189.0, 157.7, 135.8, 134.1, 133.5, 133.3, 128.4, 126.9, 118.0, 33.7; LRFAB-MS (3-NOBA matrix): m/z 208 [M+H]⁺; m.p. 82-84°C.




To a solution of **12** (100 mg, 0.48 mmol) in CHCl₃/*i*PrOH (2.40 mL/1.60 mL) was added silica (90 mg). The mixture was cooled in an ice-water bath and NaBH₄ (320 mg, 12.0 equiv.) was added portion-wise. After 1 hour at 0°C, the solution was allowed to reach room temperature and filtered on Celite[®], the pad being washed with CH₂Cl₂. Evaporation and purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 9/1 to 8/2) afforded **8** as a yellow solid (40 mg, 0.19 mmol, 40%). ¹H NMR (400 MHz, CDCl₃): δ 10.92 (bs, 1H, OH), 7.98 (d, 1H, $J = 2.0$ Hz, H₁), 7.48 (d, 1H, $J = 2.0$ Hz, H₂), 6.03 to 5.93 (m, 1H, H₄), 5.15 (t, 1H, $J = 1.2$ Hz, H₅), 5.12 (dq, 1H, $J = 6.4$ Hz, $J = 1.2$ Hz, H₅), 4.65 (s, 2H, H₆), 3.48 (d, 2H, $J = 6.4$ Hz, H₃), 1.91 (bs, 1H, CH₂-OH); ¹³C NMR (100 MHz, CDCl₃): δ 152.8, 136.4, 135.1, 133.3, 132.5, 131.9, 121.2, 117.2, 64.0, 33.9; LRESI-MS (negative): m/z 208 [M-H]⁻; m.p. 40-42°C.




To a solution of **12** (570 mg, 2.75 mmol, 1.1 equiv.) in CH₃CN (30 mL) cooled in an ice-water bath was added α -D-galactopyranosyl bromide-2,3,4,6-tetraacetate (1.03 g, 2.51 mmol) and Ag₂O (872 mg, 1.5 equiv.). After overnight stirring at room temperature, the solution was filtered through silica, eluted with ethyl acetate and concentrated under reduced pressure. Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 85/15 then 6/4) afforded **13** as a pale yellow powder (1.16 g, 2.16 mmol, 79%). ¹H NMR (400 MHz, CDCl₃): δ 9.97 (s, 1H, CHO),

8.11 (d, 1H, $J = 2.0$ Hz, H₇), 7.96 (d, 1H, $J = 2.0$ Hz, H₈), 5.96 to 5.86 (m, 1H, H₁₀), 5.48 (dd, 1H, $J = 10.4$ Hz, $J = 8.0$ Hz, H₂), 5.37 (d, 1H, $J = 2.8$ Hz, H₄), 5.22 to 5.14 (m, 2H, H₁₁), 5.05 (dd, 1H, $J = 10.4$ Hz, $J = 2.8$, H₃), 4.95 (d, 1H, $J = 8.0$ Hz, H₁), 4.02 (d, 2H, $J = 6.8$ Hz, H₆), 3.81 (dt, 1H, $J = 6.8$ Hz, $J = 0.8$ Hz, H₅), 3.58 (dd, 2H, $J = 6.4$ Hz, $J = 1.2$ Hz, H₉), 2.18 (s, 3H, *H*-Ac), 2.16 (s, 3H, *H*-Ac), 1.99 (s, 3H, *H*-Ac), 1.96 (s, 3H, *H*-Ac); ¹³C NMR (100 MHz, CDCl₃): δ 189.1, 170.3, 170.2, 170.1, 169.6, 149.6, 145.5, 139.2, 134.7, 134.6, 133.1, 124.1, 118.3, 102.3, 71.5, 70.6, 68.7, 66.6, 60.8, 34.1, 20.9, 20.8, 20.7, 20.6; LRFAB-MS (3-NOBA matrix): m/z 538 [M+H]⁺, 560 [M+Na]⁺; HRFAB-MS (3-NOBA matrix): m/z 538.1552 (calcd. for C₂₄H₂₈NO₁₃ 538.1561 [M+H]⁺); m.p. 78-80°C.




14

To a solution of **13** (700 mg, 1.30 mmol) in CHCl₃/*i*PrOH (20 mL/14 mL) was added silica (1.0 g). The mixture was cooled in an ice-water bath and NaBH₄ (594 mg, 12.0 equiv.) was added portion-wise. After 2 hours at 0°C, the solution was allowed to reach room temperature and filtered on Celite[®], the pad being washed with CH₂Cl₂. Evaporation and purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 6/4 to 3/7) afforded **14** as a pale yellow powder (608 mg, 1.13 mmol, 87%). ¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, 1H, $J = 2.0$ Hz, H₉), 7.40 (d, 1H, $J = 1.6$ Hz, H₁₁), 5.93 to 5.83 (m, 1H, H₁₄), 5.45 (dd, 1H, $J = 10.4$ Hz, $J = 8.0$ Hz, H₂), 5.35 (d, 1H, $J = 2.8$ Hz, H₄), 5.14 (bs, 1H, H₁₅), 5.11 (dd, 1H, $J = 7.2$ Hz, $J = 1.2$ Hz, H₁₅), 5.02 (dd, 1H, $J = 10.4$ Hz, $J = 3.6$ Hz, H₃), 4.82 (d, 1H, $J = 8.0$ Hz, H₁), 4.69 (bs, 2H, H₁₆), 4.03 (dd, 2H, $J = 6.8$ Hz, $J = 3.6$ Hz, H₆), 3.77 (t, 1H, $J = 6.4$ Hz, H₅), 3.50 (t, 2H, $J = 4.8$ Hz, H₁₃), 2.37 (bs, 1H, CH₂-OH), 2.18 (s, 3H, *H*-Ac), 2.15 (s, 3H, *H*-Ac), 1.98 (s, 3H, *H*-Ac), 1.96 (s, 3H, *H*-Ac); ¹³C NMR (100 MHz, CDCl₃): δ 170.5, 170.4, 170.2, 169.7, 145.3, 144.4, 139.0, 137.5, 135.6, 132.2, 121.0, 117.4, 102.7, 71.2, 70.7, 68.7, 66.7, 63.5, 60.8, 34.1, 21.1, 20.9, 20.7, 20.6 LRFAB-MS (3-NOBA matrix): m/z 538 [M+H]⁺, 562 [M+Na]⁺; HRFAB-MS (3-NOBA matrix): m/z 562.1528 (calcd. for C₂₄H₂₉NO₁₃Na 562.1537 [M+Na]⁺); m.p. 110-112°C.



To a solution of **14** (433 mg, 0.80 mmol) in CH₂Cl₂ (15 mL) was added *para*-nitrophenyl chloroformate (356 mg, 2.2 equiv.) and pyridine (160 μL, 2.5 equiv.). After one day at room temperature, the solution was diluted with water and extracted with CH₂Cl₂. The combined organic layers were washed with water, dried over MgSO₄ and concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 6/4) afforded **15** (540 mg, 0.77 mmol, 96%) as a white powder. ¹H NMR (400 MHz, CDCl₃): δ 8.29 (d, 2H, *J* = 9.2 Hz, H₁₄), 7.71 (d, 1H, *J* = 2.0 Hz, H₇), 7.50 (d, 1H, *J* = 2.0 Hz, H₈), 7.39 (d, 2H, *J* = 9.2 Hz, H₁₃), 5.96 to 5.85 (m, 1H, H₁₀), 5.48 (dd, 1H, *J* = 10.8 Hz, *J* = 8.0 Hz, H₂), 5.38 (d, 1H, *J* = 2.4 Hz, H₄), 5.27 (bs, 2H, H₁₂), 5.20 to 5.14 (m, 2H, H₁₁), 5.05 (dd, 1H, *J* = 10.8 Hz, *J* = 3.6 Hz, H₃), 4.88 (d, 1H, *J* = 8.0 Hz, H₁), 4.06 (t, 2H, *J* = 6.8 Hz, H₆), 3.80 (t, 1H, *J* = 7.6 Hz, H₅), 3.56 (t, 2H, *J* = 6.0 Hz, H₉), 2.20 (s, 3H, *H*-Ac), 2.17 (s, 3H, *H*-Ac), 2.01 (s, 3H, *H*-Ac), 1.97 (s, 3H, *H*-Ac); ¹³C NMR (100 MHz, CDCl₃): δ 170.4, 170.3, 170.2, 169.7, 155.4, 152.4, 145.7, 145.4, 138.5, 135.3, 134.1, 132.1, 125.5, 122.9, 121.8, 118.0, 102.7, 71.3, 70.7, 69.1, 68.7, 66.7, 60.8, 34.1, 20.9, 20.8, 20.7, 20.6; LRFAB-MS (3-NOBA matrix): *m/z* 705 [M+H]⁺, 727 [M+Na]⁺; m.p. 66-68°C.



CAS Registry Number: 2503-35-7

To a solution of Cbz-glycine (3.62 g, 17.3 mmol), EDCI.HCl (3.31 g, 1.0 equiv.) and DMAP (2.11 g, 1.0 equiv.) in CH₂Cl₂ (180 mL) at room temperature, was added glycyglycine ethylester hydrochloride (3.74 g, 1.1 equiv.) and the reaction mixture was stirred overnight. An aqueous solution of HCl (1 M) (100 mL) was added, the layers were separated and the aqueous layer was extracted with CHCl₃/iPrOH (3:1) (3×50 mL). The combined organic fractions were dried (MgSO₄) and concentrated under reduced pressure. To the crude solid was added Et₂O (50 mL). The resulting white suspension was sonicated for 5 minutes and filtered by gravity to give **S2** as a


colourless solid (5.42 g, 15.4 mmol, 90%). ^1H NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (1:1)): δ 7.38-7.20 (m, 5H, H_{1+2+3}), 5.06 (s, 2H, H_4), 4.15 (q, 2H, $J = 7.1$ Hz, H_8), 3.99-3.74 (m, 6H, H_{5+6+7}), 3.30 (t, 3H, $J = 7.1$ Hz, H_8); ^{13}C NMR (100 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (3:1)): δ 170.8, 170.3, 170.2, 136.2, 128.6, 128.3, 128.1, 107.0, 67.3, 61.7, 44.3, 42.4, 41.1, 14.0; LRESI-MS: m/z 374 $[\text{M}+\text{Na}]^+$; HRESI-MS: m/z 374.1321 $[\text{M}+\text{Na}]^+$ (calcd. for $\text{C}_{16}\text{H}_{21}\text{O}_6\text{N}_3\text{Na}_1$ 374.1323 $[\text{M}+\text{Na}]^+$); m.p. 133-135°C.



S3

CAS Registry Number: 2566-20-3


To a solution of **S2** (2.24 g, 6.37 mmol) in a 2:3:3 mixture $\text{H}_2\text{O}/\text{EtOH}/\text{THF}$ (320 mL) at 0°C was added crushed NaOH (395 mg, 1.5 equiv.) in one portion and the reaction mixture was stirred at that temperature for 20 min. An aqueous solution (1 M) of HCl (40 mL) was added and solvents were evaporated under reduced pressure. To the resulting solid was added H_2O (30 mL), the suspension was sonicated for 5 minutes, filtered under suction and washed with H_2O (50 mL). The solid was re-suspended in a 1:6 mixture of MeOH/ Et_2O (50 mL), sonicated for 5 minutes, filtered by gravity and washed with Et_2O (20 mL) to afford **S3** as a colourless solid (1.70 g, 5.25 mmol, 82%). ^1H NMR (400 MHz, DMSO d_6): δ 12.58 (s, 1H, H_{11}), 8.16 (dt, $J = 5.6$ Hz and $J = 5.6$ Hz, 2H, H_{5+4}), 7.49 (t, $J = 6.0$ Hz, 1H, H_9), 7.14-7.25 (m, 5H, H_{1+2+3}), 5.03 (s, 2H, H_4), 3.75 (dd, $J = 5.5$ Hz and $J = 5.5$ Hz, 4H, H_{6+8}), 3.67 (d, $J = 6.0$ Hz, 2H, H_{10}); ^{13}C NMR (100 MHz, DMSO d_6): δ 171.0, 169.3, 169.0, 156.4, 136.9, 128.2, 127.7, 127.6, 65.4, 43.4, 41.6, 40.4; LRESI-MS: m/z 346 $[\text{M}+\text{Na}]^+$; HRESI-MS: m/z 324.1196 $[\text{M}+\text{H}]^+$ (calcd. for $\text{C}_{14}\text{H}_{18}\text{O}_6\text{N}_3$ 324.1190 $[\text{M}+\text{H}]^+$); m.p. 182-184°C.




S4

To a solution of **S3** (1.52 g, 4.7 mmol), EDCI.HCl (991 mg, 1.1 equiv.) and DMAP (631 mg, 1.1 equiv.) in CH_2Cl_2 (100 mL) at room temperature, was added 2,2-diphenylethanamine (878 mg, 4.4 mmol, 0.95 equiv.) and the reaction mixture was stirred overnight. An aqueous solution (1 M) of HCl (50 mL) was added, the layers

were separated and the aqueous layer was extracted with CH_2Cl_2 (3×50 mL). The combined organic fractions were washed with H_2O (40 mL), dried (MgSO_4) and concentrated under reduced pressure to afford **S4** as a colourless solid (1.87 g, 3.72 mmol, 80%). ^1H NMR (400 MHz, $\text{DMSO } d_6$): δ 8.13, 8.05, 7.49 (3t, $J = 5.6$ Hz, $J = 5.8$ Hz and $J = 6.0$ Hz, 3H, H_{5+7+9}), 7.86 (t, $J = 5.5$ Hz, 1H, H_{11}), 7.38-7.09 (m, 15H, $\text{H}_{1+2+3+14+15+16}$), 5.03 (s, 2H, H_4), 4.18 (t, $J = 7.7$ Hz, 1H, H_{13}), 3.75-3.67 (m, 4H, H_{6+11}), 3.66, 3.58 (2d, $J = 6.1$ Hz and $J = 5.7$ Hz, 4H, H_{8+10}); ^{13}C NMR (100 MHz, $\text{DMSO } d_6$): δ 169.4, 168.9, 168.6, 156.4, 142.7, 136.9, 128.3, 128.2, 127.8, 127.7, 127.6, 126.3, 65.4, 49.9, 43.4, 43.0, 41.9, 41.7; LRESI-MS: m/z 525 $[\text{M}+\text{Na}]^+$; HRESI-MS: m/z 503.2286 $[\text{M}+\text{H}]^+$ (calcd. for $\text{C}_{28}\text{H}_{30}\text{O}_5\text{N}_4$ 503.2289 $[\text{M}+\text{H}]^+$); m.p. 210-212°C.




A solution of **S4** (2.65 g, 5.27 mmol) in a 3:4:13 mixture $\text{H}_2\text{O}/\text{MeOH}/\text{THF}$ (500 mL) was heated up to 50°C until it had fully dissolved (5 min). The solution was then allowed to cool to room temperature and palladium (10%) on carbon (561 mg) was added in one portion. The reaction vessel was purged with H_2 by means of three vacuum/ H_2 cycles and the mixture stirred at room temperature for 15 hours. The solid was filtered off with Celite[®], MeOH and THF were evaporated under reduced pressure and the remaining aqueous layer was extracted with $\text{CHCl}_3/\text{iPrOH}$ (3/1) (3×50 mL). The combined organic fractions were dried (MgSO_4) and concentrated under reduced pressure. The resulting yellow oil was re-dissolved in CH_2Cl_2 (10 mL) and Et_2O (50 mL) was added. The resulting precipitate was sonicated for 5 minutes and filtered by gravity to afford **6** as a colourless solid (1.30 g, 3.52 mmol, 67%). ^1H NMR (400 MHz, CDCl_3): δ 8.07-7.81 (m, 1H, H_6), 7.42-7.25, 6.75-6.58 (2m, 2H, H_{2+4}), 7.25-6.95 (m, 10H, $\text{H}_{9+10+11}$), 4.10 (t, 1H, $J = 7.8$ Hz, H_8), 3.75-3.67 (m, 4H, H_{6+11}), 3.75, 3.64, 3.28 (3s, 4H, H_{3+5+7}); ^{13}C NMR (100 MHz, CDCl_3): δ 169.7 ($\times 2$), 169.0, 141.7, 128.6, 128.0, 126.7, 50.2, 43.8 ($\times 2$), 42.8, 42.6 LRESI-MS: m/z 391 $[\text{M}+\text{Na}]^+$; HRESI-MS: m/z 369.1924 (calcd. for $\text{C}_{20}\text{H}_{25}\text{O}_3\text{N}_4$ 369.1921 $[\text{M}+\text{H}]^+$); m.p. 50-52°C.



16


To a solution of **15** (529 mg, 0.75 mmol) in CH₃CN (35 mL) was added the peptide **6** (332 mg, 1.2 equiv.) and Et₃N (260 μL, 2.5 equiv.). Stirring was continued at room temperature during one day and the solution was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried over MgSO₄ and concentrated. Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 4/6 to 2/8 then CH₂Cl₂/MeOH: 9/1) yielded **16** as a pale brown powder (599 mg, 0.64 mmol, 85%). ¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, 1H, *J* = 2.0 Hz, H₇), 7.39 (m, 2H, NH₁₅₊₁₇), 7.37 (d, 1H, *J* = 2.0 Hz, H₈), 7.27 to 7.16 (m, 10H, H₂₂₊₂₃₊₂₄), 6.65 (t, 1H, *J* = 5.2 Hz, NH₁₉), 6.08 (t, 1H, *J* = 4.8 Hz, NH₁₃), 5.93 to 5.82 (m, 1H, H₁₀), 5.46 (dd, 1H, *J* = 10.4 Hz, *J* = 8.0 Hz, H₂), 5.37 (d, 1H, *J* = 2.8 Hz, H₄), 5.15 (d, 1H, *J* = 1.2 Hz, H₁₁), 5.12 (dd, 1H, *J* = 9.2 Hz, *J* = 1.2 Hz, H₁₁), 5.06 (dd, 1H, *J* = 10.4 Hz, *J* = 2.8 Hz, H₃), 5.00 (s, 2H, H₁₂), 4.85 (d, 1H, *J* = 8.0 Hz, H₁), 4.17 (t, 1H, *J* = 8.0 Hz, H₂₁), 4.03 (d, 2H, *J* = 6.4 Hz, H₆), 3.91 to 3.76 (m, 9H, H₅₊₁₄₊₁₆₊₁₈₊₂₀), 3.50 (m, 2H, H₉), 2.19 (s, 3H, *H*-Ac), 2.15 (s, 3H, *H*-Ac), 2.00 (s, 3H, *H*-Ac), 1.95 (s, 3H, *H*-Ac); ¹³C NMR (100 MHz, CDCl₃): δ 170.5, 170.4, 170.2, 169.8, 169.7, 169.3, 168.9, 156.4, 145.4, 145.0, 141.9, 137.9, 135.4, 134.4, 133.5, 128.8, 128.1, 126.9, 122.2, 117.7, 102.7, 71.1, 70.7, 68.8, 66.7, 65.3, 60.7, 50.5, 44.4, 44.0, 43.1, 42.9, 34.0, 29.8, 20.9, 20.8, 20.7, 20.6; LRESI-MS: *m/z* 957 [M+Na]⁺; LRFAB-MS (3-NOBA matrix): *m/z* 935 [M+H]⁺; HRFAB-MS (3-NOBA matrix): *m/z* 934.3384 (calcd. for C₄₅H₅₂N₅O₁₇ 934.3359 [M+H]⁺); m.p. 126-128°C.



21


To a solution of **16** (100 mg, 0.11 mmol) in MeOH (10 mL) cooled in an ice-water bath was added dropwise a 0°C solution of MeONa (58 mg, 10.0 equiv.) in MeOH (5 mL). Stirring was continued for one hour at 0°C and the solution was neutralised with

Amberlite IRC-50 and filtered. MeOH was then evaporated and the resulting mixture was purified by column chromatography over silica gel (CH₂Cl₂/MeOH: 5 to 20% MeOH) to afford **21** (57 mg, 0.07 mmol, 64%) as a pale brown powder. ¹H NMR (400 MHz, CD₃OD): δ 7.57 (d, 1H, *J* = 2.0 Hz, H₇), 7.45 (d, 1H, *J* = 2.0 Hz, H₈), 7.24 to 7.19 (m, 8H, H₂₂₊₂₃), 7.14 to 7.10 (m, 2H, H₂₄), 5.99 to 5.89 (m, 1H, H₁₀), 5.11 to 5.04 (m, 4H, H₁₁₊₁₂), 4.47 (d, 1H, *J* = 8.0 Hz, H₁), 4.24 (t, 1H, *J* = 8.0 Hz, H₂₁), 3.80 to 3.73 (m, 8H, H₁₄₊₁₆₊₁₈₊₂₀), 3.70 (m, 2H, H₄₊₅), 3.66 to 3.54 (m, 5H, H₂₊₆₊₉), 3.44 (dd, 1H, *J* = 10.0 Hz, *J* = 3.6 Hz, H₃); ¹³C NMR (100 MHz, CD₃OD): δ 173.1, 172.1, 171.5, 159.0, 147.9, 147.0, 143.8, 138.5, 137.5, 135.5, 134.7, 129.6, 129.2, 127.7, 122.8, 117.4, 107.1, 77.1, 74.7, 72.5, 69.7, 66.5, 61.6, 51.6, 49.9, 45.1, 43.8, 43.3, 34.5; LRES⁺-MS: *m/z* 766 [M+H]⁺, 788-789-790 [M+Na]⁺; LRFAB-MS (3-NOBA matrix): *m/z* 766 [M+H]⁺; HRFAB-MS (3-NOBA matrix): *m/z* 766.2928 (calcd. for C₃₇H₄₄N₅O₁₃ 766.2936 [M+H]⁺); m.p. 145-147°C.




Thread **16** (200 mg, 0.21 mmol) and Et₃N (1.0 mL, 35.0 equiv.) were dissolved in anhydrous chloroform (40 mL) and stirred vigorously whilst solutions of *p*-xylylene diamine (466 mg, 16.0 equiv.) in anhydrous chloroform (40 mL) and isophthaloyl dichloride (696 mg, 16.0 equiv.) in anhydrous chloroform (40 mL) were simultaneously added over a period of 3 hours using motor-driven syringe pumps. After overnight stirring, 1 mL of MeOH was added and the resulting suspension filtered through Celite[®]. The pad was washed with CHCl₃/MeOH 2% (3 x 100 mL) and the combined filtrates were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using CH₂Cl₂/MeOH (1 to 15% MeOH) as eluent to give a mixture of thread **16** and rotaxane **S1**. This mixture was resolved by running a size exclusion chromatography using CHCl₃/MeOH (50/50) as eluent to give rotaxane **S1** as a pale brown powder (161 mg, 0.11 mmol, 51%). ¹H

NMR (400 MHz, CDCl₃): δ 8.19 (s, 2H, H_C), 8.00 (d, 4H, $J = 7.6$ Hz, H_B), 7.81 (bs, 4H, H_D), 7.47 (t, 2H, $J = 7.6$ Hz, H_A), 7.35 (s, 1H, H₇), 7.23 (s, 1H, H₈), 7.21 to 7.09 (m, 18H, H_{22+23+24+F}), 6.98 (bs, 3H, NH₁₅₊₁₇₊₁₉), 5.89 to 5.79 (m, 1H, H₁₀), 5.73 (bs, 1H, NH₁₃), 5.46 (t, 1H, $J = 8.0$ Hz, H₂), 5.37 (bs, 1H, H₄), 5.14 to 5.05 (m, 3H, H₃₊₁₁), 4.84 (d, 1H, $J = 8.0$ Hz, H₁), 4.74 (bs, 2H, H₁₂), 4.48 to 4.39 (m, 8H, H_E), 4.05 (t, 1H, $J = 8.0$ Hz, H₂₁), 4.02 (d, 2H, $J = 6.0$ Hz, H₆), 3.80 (t, 1H, $J = 6.0$ Hz, H₅), 3.70 (bs, 2H, H₂₀), 3.46 to 3.42 (m, 4H, H₉₊₁₄), 3.30 (bs, 2H, H₁₈), 2.93 (bs, 2H, H₁₆), 2.17 (s, 3H, *H*-Ac), 2.16 (s, 3H, *H*-Ac), 2.01 (s, 3H, *H*-Ac), 1.94 (s, 3H, *H*-Ac); ¹³C NMR (100 MHz, CDCl₃): δ 170.5, 170.3, 170.2, 170.1, 169.7, 169.2, 168.2, 167.2, 156.3, 145.3, 145.0, 141.7, 137.7, 137.4, 135.3, 134.3, 133.9, 133.7, 131.0, 129.1, 129.0, 128.8, 128.0, 127.0, 125.4, 122.2, 117.7, 102.6, 71.1, 70.7, 68.8, 66.7, 65.3, 60.7, 50.5, 44.5, 44.2, 42.7, 42.1, 33.9, 20.9, 20.8, 20.7, 20.6; LRFAB-MS (3-NOBA matrix): m/z 1467 [M+H]⁺; HRFAB-MS (3-NOBA matrix): m/z 1466.5485 (calcd. for C₇₇H₈₀N₉O₂₁ 1466.5469 [M+H]⁺); m.p. 160-162°C.




To a solution of **S1** (98 mg, 0.067 mmol) in MeOH (10 mL) cooled in an ice-water bath was added dropwise a 0°C solution of MeONa (36 mg, 10.0 equiv.) in MeOH (5 mL). Stirring was continued for one hour at 0°C and the solution was neutralised with Amberlite IRC-50 resin and filtered. MeOH was then evaporated and the resulting mixture was purified by column chromatography over silica gel (CH₂Cl₂/MeOH: 2 to 10% MeOH) to afford **22** (75 mg, 0.058 mmol, 87%) as a pale brown powder. ¹H NMR (400 MHz, CD₃OD): δ 8.34 (bs, 2H, H_C), 8.05 to 8.03 (m, 4H, H_B), 7.59 (t, 2H, $J = 7.6$ Hz, H_A), 7.23 to 7.01 (m, 18H, H_{22+23+24+F}), 5.97 to 5.87 (m, 1H, H₁₀), 5.09 (dd, 1H, $J = 8.8$ Hz, $J = 1.6$ Hz, H₁₀), 5.05 (bs, 1H, H₁₁), 4.57 (bs, 2H, H₁₂), 4.48 to 4.39 (m, 9H), 3.93 (t, 1H, $J = 8.0$ Hz, H₂₁), 3.82 (t, 1H, $J = 3.2$ Hz), 3.76 (dd, 1H, $J = 9.6$ Hz, $J = 7.6$ Hz), 3.65 (dd, 1H, $J = 11.2$ Hz, $J = 6.8$ Hz), 3.57 to 3.44 (m, 10H,


3H, *H*-Ac), 1.93 (s, 3H, *H*-Ac), 1.88 (s, 3H, *H*-Ac); ^{13}C NMR (100 MHz, CDCl_3): δ 170.6, 170.4, 170.2, 169.7, 169.4, 168.1, 166.0, 156.5, 145.3, 145.1, 141.6, 141.5, 137.8, 137.2, 135.7, 135.3, 133.8, 133.5, 129.3, 128.9, 127.9, 127.2, 122.1, 121.6, 121.0, 117.8, 102.7, 71.1, 70.7, 68.7, 66.7, 65.4, 60.7, 53.9, 50.6, 44.5, 44.4, 42.9, 42.4, 34.0, 31.9, 29.4, 21.0, 20.8, 20.7 (x2); LRESI-MS: m/z 1550 $[\text{M}+\text{H}]^+$; LRFAB-MS (3-NOBA matrix): m/z 1551 $[\text{M}+\text{H}]^+$; m.p. degradation.



To a solution of peracetylated β -D-glucose (317 mg, 0.81 mmol) and alkyne **17** (283 mg, 1.5 equiv.) in anhydrous CH_2Cl_2 (2 mL) under N_2 at 0°C , was added $\text{BF}_3\cdot\text{Et}_2\text{O}$ (0.52 mL, 5.0 equiv.) dropwise. The reaction mixture was allowed to warm up to room temperature and stirred overnight. An aqueous saturated solution of NaHCO_3 (10 mL) was added, the layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3 \times 15 mL). The combined organic fractions were dried (Na_2SO_4) and concentrated under reduced pressure. The resulting brown residue was purified by flash column chromatography on silica gel with CH_2Cl_2 /acetone (93/7) as eluent to give pure **18** as a colourless oil (378 mg, 0.67 mmol, 83%). ^1H NMR (400 MHz, CDCl_3): δ 5.13 (t, 1H, $J = 9.6$ Hz, H_3), 5.01 (t, 1H, $J = 9.6$ Hz, H_4), 4.91 (dd, 1H, $J = 8.0$ Hz, $J = 9.6$ Hz, H_2), 4.55 (d, 1H, $J = 8.0$ Hz, H_1), 4.19 (dd, 1H, $J = 4.7$ Hz, $J = 12.3$ Hz, H_6), 4.14 (d, 2H, $J = 2.4$ Hz, H_{15}), 4.06 (dd, 1H, $J = 2.3$ Hz, $J = 12.3$ Hz, H_6), 3.87 (dt, 1H, $J = 4.0$ Hz, $J = 11.0$ Hz, H_7), 3.71 to 3.52 (m, 16H, $\text{H}_{5+7'+8+9+10+11+12+13+14}$), 2.40 (t, 1H, $J = 2.3$ Hz, H_{16}), 2.01, 1.97, 1.95, 1.93 (4s, 12H, *H*-Ac); ^{13}C NMR (100 MHz, CDCl_3): δ 170.4, 170.0, 169.2, 169.1, 100.6, 79.5, 74.4, 72.6, 71.5, 71.0, 70.5, 70.4 ($\times 2$), 70.3, 70.1, 70.0, 68.8 ($\times 2$), 68.2, 61.7, 58.1, 20.6, 20.5, 20.4, 20.3; LRESI-MS: m/z 585 $[\text{M}+\text{Na}]^+$; HRESI-MS: m/z 580.2600 (calcd. for $\text{C}_{25}\text{H}_{42}\text{O}_{14}\text{N}$ 580.2600 $[\text{M}+\text{NH}_4]^+$).




To a solution of rotaxane **1** (100 mg, 64.60 μmol) and alkyne **17** (30 mg, 2.0 equiv.) in CH_2Cl_2 (10 mL) was added $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (12 mg, 0.5 equiv.) and Et_3N (20 μL , 2.2 equiv.) and the solution stirred overnight at room temperature. A saturated NH_4Cl solution was then added to the reaction mixture and air was bubbled for 30 min. The organic layer was separated and washed with 1M EDTA, dried over MgSO_4 , filtrated and concentrated under reduced pressure. The resulting solid was purified by column chromatography on silica gel using $\text{CHCl}_3/\text{acetone}$ (30 to 55% acetone) to give rotaxane **19** as a pale yellow powder (31 mg, 15.40 μmol , 24%). ^1H NMR (400 MHz, CDCl_3): δ 8.31 (bs, 6H, $\text{H}_{\text{A}+\text{F}}$), 8.22 (bs, 2H, H_{B}), 8.18 (bs, 4H, H_{C}), 7.35 (s, 1H, H_7), 7.18 (s, 1H, H_8), 7.09 to 6.99 (m, 21H, $\text{H}_{\text{E}+22+23+24+15+17+19}$), 5.96 (bs, 1H, H_{13}), 5.79 to 5.69 (m, 1H, H_{10}), 5.36 (dd, 1H, $J = 10.4$ Hz, $J = 8.0$ Hz, H_2), 5.30 (d, 1H, $J = 3.2$ Hz, H_4), 5.03 to 4.98 (m, 3H, H_{3+11}), 4.77 to 4.74 (m, 3H, H_{1+12}), 4.68 (bs, 4H, H_{G}), 4.39 to 4.35 (m, 8H, H_{D}), 3.97 to 3.94 (m, 3H, H_{6+21}), 3.77 (t, 1H, $J = 6.8$ Hz, H_5), 3.69 to 3.47 (m, 34H, $\text{H}_{20+\text{H}+1+\text{J}+\text{K}+\text{L}+\text{M}+\text{N}+\text{O}$), 3.37 to 3.35 (m, 2H, H_9), 2.96 to 2.79 (m, 7H, $\text{H}_{14+16+18}$), 2.11 (s, 3H, *H*-Ac), 2.06 (s, 3H, *H*-Ac), 1.93 (s, 3H, *H*-Ac), 1.87 (s, 3H, *H*-Ac); ^{13}C NMR (100 MHz, CDCl_3): δ 170.6, 170.4, 170.2, 170.1, 170.0, 169.7, 169.2, 168.6, 166.0 (x2), 156.3, 146.2, 145.3, 145.0, 141.9, 137.7, 137.3, 137.2, 136.3, 136.2, 135.4, 134.2, 133.4, 129.1, 128.7, 128.0, 126.9, 126.2, 122.0, 121.4, 117.7, 102.6, 72.7, 71.1, 70.7, 70.5 (x2), 70.2, 70.1, 68.8, 66.7, 65.2, 64.6, 61.5, 60.7, 50.5, 44.7, 44.2, 42.4, 41.8, 34.0, 29.8, 20.9, 20.8, 20.7 (x2); LRFAB-MS (3-NOBA matrix): m/z 2014 $[\text{M}+\text{H}]^+$, 2036 $[\text{M}+\text{Na}]^+$; HRFAB-MS (3-NOBA matrix): m/z 2013.8153 (calcd. for $\text{C}_{98}\text{H}_{118}^{13}\text{CN}_{15}\text{O}_{31}$ 2013.8152 $[\text{M}+\text{H}]^+$).




To a solution of rotaxane **1** (70 mg, 45.20 μmol) and alkyne **18** (51 mg, 2.0 equiv.) in CH_2Cl_2 (7 mL) was added $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (8 mg, 0.5 equiv.) and Et_3N (14 μL , 2.2 equiv.) and the solution was stirred overnight at room temperature. A saturated NH_4Cl solution was then added to the reaction mixture and air was bubbled for 30 min. The organic layer was separated and washed with 1M EDTA, dried over MgSO_4 , filtrated and concentrated under reduced pressure. The resulting solid was purified by preparative TLC on silica eluted 4 times with $\text{CHCl}_3/\text{acetone}$ (1:1) as eluent to give rotaxane **20** as a pale yellow powder (84 mg, 31.6 μmol , 70%). ^1H NMR (400 MHz, CDCl_3): δ 8.38 (bs, 2H, H_B), 8.34 (bs, 2H, H_F), 8.25 to 8.19 (m, 8H, $\text{H}_{\text{A}+\text{C}}$), 7.40 (s, 1H, H_7), 7.22 (s, 1H, H_8), 7.18 to 6.95 (m, 21H, $\text{H}_{15+17+19+22+23+24+\text{E}}$), 5.85 to 5.75 (m, 2H, H_{10+13}), 5.43 (dd, 1H, $J = 10.4$ Hz, $J = 8.0$ Hz, H_2), 5.37 (d, 1H, $J = 3.6$ Hz, H_4), 5.20 (t, 2H, $J = 9.6$ Hz, H_R), 5.10 to 5.04 (m, 5H, $\text{H}_{3+11+\text{S}}$), 5.97 (dd, 2H, $J = 9.6$ Hz, $J = 8.0$ Hz, H_Q), 4.82 (m, 3H, H_{1+12}), 4.76 (bs, 4H, H_G), 4.58 (d, 2H, $J = 8.0$ Hz, H_P), 4.55 to 4.43 (m, 8H, H_D), 4.24 (dd, 2H, $J = 12.0$ Hz, $J = 4.4$ Hz, H_U), 4.11 (dd, 2H, $J = 12.0$ Hz, $J = 2.0$ Hz, H_U), 4.07 to 3.98 (m, 3H, H_{6+21}), 3.77 to 3.76 (m, 3H, $\text{H}_{5+\text{T}}$), 3.72 to 3.56 (m, 36H, $\text{H}_{14+20+\text{H}+\text{I}+\text{J}+\text{K}+\text{L}+\text{M}+\text{N}+\text{O}$), 3.42 (d, 2H, $J = 6.4$ Hz, H_9), 3.34 to 3.25 (m, 2H, H_{18}), 2.84 (bs, 2H, H_{16}), 2.17 (s, 3H, H-Ac), 2.13 (s, 3H, H-Ac), 2.06 (s, 6H, H-Ac), 2.03 (s, 6H, H-Ac), 2.01 (s, 6H, H-Ac), 2.00 (s, 3H, H-Ac), 1.99 (s, 6H, H-Ac), 1.95 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 170.9, 170.4 (x2), 170.2, 169.7, 169.6, 165.8, 146.5, 145.0, 141.8, 137.7, 137.4, 137.3, 136.4, 136.3, 135.3, 134.1, 133.3, 129.9, 129.1, 128.8, 128.0, 126.9, 126.1, 121.9 (x2), 121.2, 117.7, 102.6, 101.0 (x2), 72.9, 71.9, 71.4, 71.0, 70.7, 70.6, 70.3, 70.1, 69.3, 68.8, 68.5, 66.8, 65.2, 64.6, 62.1, 60.7, 50.5, 44.7, 44.3, 44.1, 42.4, 42.3, 41.8, 33.9, 29.8, 29.4, 21.0, 20.9 (x2),


20.8, 20.7; LRFAB-MS (3-NOBA matrix): m/z 2675 $[M+H]^+$, 2699 $[M+Na]^+$;
HRFAB-MS (3-NOBA matrix): m/z 2695.9802 (calcd. for $C_{126}^{13}CH_{153}N_{15}O_{49}Na$
calcd. 2695.9873 $[M+Na]^+$); m.p. 133-135°C.




To a solution of **19** (27 mg, 13.40 μmol) in MeOH (4 mL) cooled in an ice-water bath was added dropwise at 0°C solution of MeONa (7 mg, 10.0 equiv.) in MeOH (2 mL). Stirring was continued for one hour at 0°C and the solution was neutralised with Amberlite IR-120 resin and filtered. MeOH was then evaporated and the resulting mixture was purified by preparative RP-HPLC using a linear gradient (37 to 55% in 20 min) of CH_3CN (containing 6.6 mM of HCOOH) in H_2O (containing 6.6 mM of HCOOH) at a flow rate of 10 ml/min to give rotaxane **2** as a pale yellow solid (17 mg, 9.40 μmol , 70%). Purity (HPLC): >94%. ^1H NMR (400 MHz, CD_3OD): δ 8.57 (s, 2H, H_B), 8.36 (s, 4H, H_A), 8.29 (s, 2H, H_F), 7.16 to 6.89 (m, 20H, $\text{H}_{7+8+22+23+24+E}$), 5.78 to 5.68 (m, 1H, H_{10}), 4.95 to 4.90 (m, 2H, H_{11}), 4.45 to 4.34 (m, 12H, H_{D+G}), 4.21 (d, 1H, $J = 8.0$ Hz, H_I), 3.88 (t, 1H, $J = 8.0$ Hz, H_{21}), 3.69 to 3.28 (m, 52H, $\text{H}_{2+3+4+5+6+9+12+14+16+18+20+H+I+J+K+L+M+N+O}$); ^{13}C NMR (100 MHz, CD_3OD): δ 171.2, 167.5, 167.4, 158.1, 147.4, 143.6, 138.7 (x2), 137.4, 134.4, 130.0, 129.6, 129.0, 127.8, 127.7, 127.3, 123.5, 123.1, 123.0, 122.6, 117.4, 106.9, 77.1, 74.6, 73.6, 72.4, 71.6, 71.5, 71.4, 71.0, 69.7, 66.1, 65.0, 62.2, 61.8, 51.7, 45.2, 45.0, 43.1, 42.8, 34.3, 30.8; m.p. 102-104°C.



To a solution of **20** (24 mg, 9.00 μmol) in MeOH (4 mL) cooled in an ice-water bath was added dropwise at 0°C solution of MeONa (16 mg, 30.0 equiv.) in MeOH (3 mL). Stirring was continued for one hour at 0°C and the solution was neutralised with Amberlite IRC-50 resin and filtered. MeOH was then evaporated and the resulting mixture was purified by preparative RP-HPLC using a linear gradient (33 to 45 % in 15 min) of MeCN (containing 6.6 mM of HCOOH) in H₂O (containing 6.6 mM of HCOOH) at a flow rate of 10 mL/min to give rotaxane **3** as a pink solid (12 mg, 5.50 μmol , 61%). Purity (HPLC): >94%. ¹H NMR (400 MHz, CD₃OD): δ 8.69 (s, 2H, H_B), 8.47 (s, 4H, H_A), 8.39 (s, 2H, H_F), 7.41-6.92 (m, 20H, H_{7+8+22+23+24+E}), 5.92-5.77 (m, 1H, H₁₀), 5.07-4.98 (m, 2H, H₁₁), 4.78 (s, 4H, H_G), 4.56-4.38 (m, 8H, H_D), 4.32 (d, J = 7.7 Hz, 2H, H_I), 4.29 (d, J = 7.8 Hz, 2H, H_P), 4.04-3.93 (m, 3H, H_{O+21}), 3.90-3.10 (m, 52H, H_{H+I+J+K+L+M+N+O'+U+2+3+4+5+6+9+12+14+16+18+20}); ¹³C NMR (100 MHz, CD₃OD): δ 172.5, 171.2, 170.6, 167.5, 167.4, 158.1, 147.4, 146.8, 143.6, 138.8, 138.7, 138.2, 137.4, 134.7, 134.5, 130.0 ($\times 2$), 129.6, 129.5, 129.0 ($\times 2$), 127.9, 127.7, 123.6, 123.2, 123.1, 122.6, 117.4, 106.9, 104.4, 78.0, 77.9, 77.1, 75.1, 74.6, 72.4, 71.7, 71.6, 71.6, 71.5, 71.4, 71.0, 69.7, 69.6, 66.1, 65.0, 62.8, 61.8, 51.7, 45.2, 45.0, 43.1, 42.8, 34.3; LRESI-MS: m/z 1085.4 [M+2H]²⁺; isotopic distribution matches that calculated for C₁₀₃H₁₃₁N₁₅O₃₇; m.p. 129-131°C (decomposition).




To a solution of 5-amino-pentan-1-ol (3.0 g, 29.10 mmol) in dry DMF (40 mL) at 0 °C was added a solution of fumaroyl dichloride (0.90 g, 2.0 equiv.) in DMF (15 mL) over a period of 2 hours using motor-driven syringe pumps. The reaction mixture was stirred for a further 2 hours, concentrated under reduced pressure. The residue was re-dissolved in CH₂Cl₂ (300 mL) and a solution of HCl (3 M) in diethyl ether was added until all of the unreacted 5-aminopentan-1-ol had precipitated. The solid was filtered through a plug of Celite[®], the plug was washed with warm DMF (2×15 mL) and solvents were removed under reduced pressure to afford **S5** as a pale yellow solid. (1.16 g, 4.05 mmol, 70%). ¹H NMR (400 MHz, DMSO *d*₆): δ 8.36 (t, 2H, *J* = 5.6 Hz, H₆), 6.80 (s, 2H, H₇), 3.36 (t, 4H, *J* = 6.4 Hz, H₁), 3.12 (q, 4H, *J* = 6.0 Hz, H₅), 1.47-1.34 (m, 8H, H₂+H₄), 1.32-1.21 (m, 4H, H₃); ¹³C NMR (100 MHz, DMSO *d*₆): δ 163.6, 132.6, 60.6, 32.2, 28.8, 28.6, 23.0; FAB-MS: *m/z* 286 [M]⁺; HRESI-MS: *m/z* 287.1967 [M+H]⁺ (calcd. for C₁₄H₂₇N₂O₄ 287.1965 [M+H]⁺); m.p. = 219-222°C.



To a solution of 3,3,3-tris-(4-chloro-phenyl)-propionic acid (1.53 g, 2.0 equiv.), EDC.HCl (0.98 g, 3.0 equiv.) and DMAP (0.63 g, 3.0 equiv.) in CH₂Cl₂ (30 mL) at room temperature, was added bis-alcohol **S5** (0.49 g, 1.71 mmol). The reaction mixture was stirred overnight. CH₂Cl₂ (250 mL) and an aqueous solution (1 M) of HCl (50 mL) were added. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (2×25 mL). The combined organic fractions were washed with an aqueous saturated solution of NaHCO₃, dried (MgSO₄) and concentrated under reduced pressure. Purification by flash column chromatography on silica using CH₂Cl₂/MeOH (98/2) as eluent gave **S6** as a colourless solid (1.50 g, 1.41 mmol, 84%). ¹H NMR (400 MHz, CDCl₃/CD₃OD: 9/1): δ 8.01 (t, 2H, *J* = 5.6 Hz, H₉), 7.23 to 7.16 (m, 12H, H₁), 7.12 to 7.04 (m, 12H, H₂), 6.71 (s, 2H, H₁₀), 3.75 (t, 4H, *J* = 6.5 Hz, H₄), 3.59 (s, 4H, H₃), 3.23 to 3.17 (m, 4H, H₈), 1.51-1.26 (m, 8H, H₅+7), 1.19 to 1.05 (m, 4H, H₆); ¹³C NMR (400 MHz, CDCl₃/CD₃OD: 9/1): δ 170.4, 164.2, 144.2, 133.0, 132.6, 130.3, 128.2, 64.3, 54.6, 46.0, 39.6, 29.0, 28.0, 23.2; LRFAB-MS: *m/z*


1061 [M+H]⁺; HRFAB-MS (glycerol matrix): *m/z* 1061.2029 (calcd. for C₅₆¹³CH₅₂D³⁵Cl₆N₂O₆ 1061.2005 [M+H]⁺); m.p. 132-136°C.




To a vigorously stirred solution of thread **S6** (0.53 g, 4.94 mmol) and Et₃N (2 mL, 30.0 equiv.) in 1 L of dry CHCl₃ under nitrogen, was simultaneously added a solution of *p*-xylylenediamine (1.00 g, 15.0 equiv.) in CHCl₃ (50 mL) and a solution of 5-azido-isophthaloyl dichloride (1.81 g, 15.0 equiv.) in CHCl₃ (50 mL) over a period of 3 hours using motor-driven syringe pumps. The reaction mixture was stirred for another 2 hours, filtered over a Celite[®] pad and the filtrate was concentrated under reduced pressure. The resulting orange solid was purified by flash column chromatography on silica with acetone/CH₂Cl₂ (10/90) as eluent to give rotaxane **S7** (0.69 g, 4.12 mmol, 83%). ¹H NMR (400 MHz, CDCl₃): δ 8.03 (m, 2H, H_C), 7.81-7.67 (m, 6H, H_{10+D}), 7.66 (s, 4H, H_B), 7.21-7.12 (m, 20H, H_{1+F}), 7.09-7.01 (m, 12H, H₂), 5.74 (s, 2H, H₁₀), 4.45 (bs, 8H, H_E), 3.72 (t, 4H, *J* = 6.5 Hz, H₄), 3.14 (m, 2H, H₈), 1.45 (bquint, 4H, *J* = 7.2 Hz, H₅), 1.37 to 1.21 (m, 4H, H₇), 1.17 to 1.05 (m, 4H, H₆); ¹³C NMR (100 MHz, CDCl₃): δ 170.3, 165.9, 165.4, 143.8, 141.6, 136.6, 135.3, 132.3, 130.0, 129.5, 128.7, 127.9, 121.4, 120.8, 64.0, 54.4, 45.7, 43.8, 39.5, 28.4, 27.7, 23.0; LRESI-MS: *m/z* 1697 [M+Na]⁺; HRESI-MS: *m/z* 1694.4408 (calcd. for C₈₈H₈₂C₁₆N₁₃O₁₀ 1694,4439 [M+NH₄]⁺); isotopic distribution matches that calculated for C₈₈H₈₂Cl₆N₁₃O₁₀; m.p. 174-176°C (decomposition)

General method to access functionalised macrocycle **9** and **10**

To a solution of rotaxane **S7**, alkyne (2.0 equiv.), and Cu(CH₃CN)₄PF₆ (0.5 equiv.) in dry CH₂Cl₂ (5 mL) and under N₂ at room temperature was added Et₃N (2.2 equiv.) and the mixture was stirred overnight. Air was bubbled through the mixture for 15 min.




Rotaxane **S8** (40 mg, 0.018 mmol) was stirred for 4 days at room temperature in a 1 M solution of NaOH in THF/H₂O/EtOH (3/2/5) (10 mL). A 1 M aqueous solution of HCl was added drop wise until pH equalled 7. The whole solution was loaded on a preparative silica TLC plate that was eluted with CH₂Cl₂/MeOH (15:85) to give macrocycle **9** as a waxy solid (18 mg, 0.016 mmol, 90%). ¹H NMR (400 MHz, CD₃OD/CDCl₃ : 1/1): δ 8.41 (2s, 4H, H_A), 8.35 (bs, 2H, H_B), 8.11 (t, 2H, *J* = 1.4 Hz, H_F), 7.28 (s, 8H, H_E), 4.53 (s, 8H, H_D), 4.70 (s, 2H, H_G), 3.72-3.49 (m, 32H, H_{H+I+J+K+L+M+N+O}); ¹³C NMR (100 MHz, CD₃OD/CDCl₃ : 1/1): δ 166.4, 137.8, 137.7, 136.9, 128.9, 125.3, 122.7, 122.1, 72.8, 70.8, 70.7, 70.6, 70.5, 70.3, 70.1, 64.4, 61.4, 44.3 (x2); LRESI-MS: *m/z* 1101 [M+Na]⁺; HRESI-MS: *m/z* 1101.4651 (calcd. for C₅₄H₆₆N₁₀O₁₄Na 1101.4652 [M+Na]⁺).




Rotaxane **S9** (122 mg, 0.050 mmol) was stirred for 48 hours at room temperature in a 10 M solution of NaOH in THF/H₂O/EtOH (1/1/1) (10 mL). A 1M aqueous solution of HCl was added drop wise until pH equalled 7. Solvents were removed under vacuum. The resulting solid was re-dissolved in a 1/1 mixture of CH₃CN/H₂O (10 mL), filtered by gravity and the filtrate used for purification by preparative RP-HPLC using a linear gradient of CH₃CN (25 to 40% in 20 min) in H₂O to give macrocycle **10** as a colourless solid (18 mg, 0.012 mmol, 25%). ¹H NMR (400 MHz, CD₃OD/CDCl₃: 1/1): δ 8.41, 8.40 (2s, 6H, H_{A+B}), 8.09 (s, 2H, H_F), 7.23 (s, 8H, H_E), 4.70 (s, 4H, H_G), 4.55-4.42 (m, 8H, H_D), 4.16 (d, *J* = 7.8 Hz, 2H, H_P), 3.95 to 3.83 (m, 2H, H_O), 3.74 (dd, 2H, *J* = 2.7 Hz, *J* = 12.1 Hz, H_U) 3.73-3.49 (m, 32H, H_{H+I+J+K+L+M+N+O'+U'}) 3.26 to 3.00 (m, 8H, H_{Q+R+S+T}); ¹³C NMR (100 MHz, CD₃OD/CDCl₃: 1/1): δ 166.5, 146.3, 137.8, 137.7, 136.8, 128.9, 125.4, 122.7, 122.2, 103.1, 76.6, 76.5, 73.8, 70.8 (x 2), 70.7, 70.6, 70.5, 70.4, 70.3, 70.0, 68.7, 64.4, 61.9, 44.3; LRESI-MS: *m/z* 1425 [M+H]⁺; HRESI-MS: *m/z* 1425.5709 (calcd. for C₆₆H₈₇N₁₀O₂₄ 1425.5709 [M+H]⁺); mp. 205-207°C.

4. Representative ^1H NMR Stack Plots




^1H NMR spectra of a) thread **16** and b) rotaxane **S1**, (400 MHz, 298 K, CDCl_3)




^1H NMR spectra of a) thread **16** and b) rotaxane **1**, (400 MHz, 298 K, CDCl_3)


5. Selected ^1H and ^{13}C NMR Spectra




^1H NMR of **18**, 400 MHz, 298 K, CDCl_3




^{13}C NMR (pendant) of **18**, 100 MHz, 298 K, CDCl_3




¹H NMR of **S7**, 400 MHz, 298 K, CDCl₃




¹³C NMR (pendant) of **S7**, 100 MHz, 298 K, CDCl₃




¹H NMR of **S8**, 400 MHz, 298 K, CDCl₃




¹³C NMR (pendant) of **S8**, 100 MHz, 298 K, CDCl₃




^1H NMR of **S9**, 400 MHz, 298 K, CDCl_3




^{13}C NMR (pendant) of **S9**, 100 MHz, 298 K, CDCl_3




¹H NMR of **9**, 400 MHz, 298 K, CD₃OD/CDCl₃: 1/1




¹³C NMR (pendant) of **9**, 100 MHz, 298 K, CD₃OD/CDCl₃: 1/1




¹H NMR of **10**, 400 MHz, 298 K, CD₃OD/CDCl₃: 1/1




¹³C NMR (pendant) of **10**, 100 MHz, 298 K, CD₃OD/CDCl₃: 1/1




^1H NMR of **12**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **12**, 100 MHz, 298 K, CDCl_3




¹H NMR of **8**, 400 MHz, 298 K, CDCl₃




¹³C NMR of **8**, 100 MHz, 298 K, CDCl₃




¹H NMR of **13**, 400 MHz, 298 K, CDCl₃




¹³C NMR of **13**, 100 MHz, 298 K, CDCl₃




¹H NMR of **14**, 400 MHz, 298 K, CDCl₃




¹³C NMR of **14**, 100 MHz, 298 K, CDCl₃




^1H NMR of **15**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **15**, 100 MHz, 298 K, CDCl_3




^1H NMR of **16**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **16**, 100 MHz, 298 K, CDCl_3




^1H NMR of **21**, 400 MHz, 298 K, CD_3OD




^{13}C NMR of **21**, 100 MHz, 298 K, CD_3OD




^1H NMR of **S1**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **S1**, 100 MHz, 298 K, CDCl_3




^1H NMR of **22**, 400 MHz, 298 K, CD_3OD




^{13}C NMR of **22**, 100 MHz, 298 K, CD_3OD




^1H NMR of **1**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **1**, 100 MHz, 298 K, CDCl_3




^1H NMR of **19**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **19**, 100 MHz, 298 K, CDCl_3




^1H NMR of **20**, 400 MHz, 298 K, CDCl_3




^{13}C NMR of **20**, 100 MHz, 298 K, CDCl_3




¹H NMR of **2**, 400 MHz, 298 K, CD₃OD



¹³C NMR of **2**, 100 MHz, 298 K, CD₃OD



^1H NMR of **3**, 400 MHz, 298 K, CD_3OD



^{13}C NMR (pendant) of **3**, 100 MHz, 298 K, CD_3OD

6. References

1. H. Ando, S. Manabe, Y. Nakahara and Y. Ito, *J. Am. Chem. Soc.*, 2001, **123**, 3848-3849.
2. X.-L. Sun, C. L. Stabler, C. S. Cazalis and E. L. Chaikof, *Bioconjugate Chem.*, 2006, **17**, 52-57.